Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AURKA | O14965 | 8/20 | 0.51 |
| ▸ | PDGFRB | P09619 | 4/20 | 0.51 |
| ▸ | CSF1R | P07333 | 2/20 | 0.51 |
| ▸ | KIT | P10721 | 2/20 | 0.51 |
| ▸ | PDGFRA | P16234 | 2/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.51 |
| ▸ | FLT4 | P35916 | 4/20 | 0.44 |
| ▸ | FLT3 | P36888 | 3/20 | 0.43 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.40 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.40 |
| ▸ | EGFR | P00533 | 3/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2800763 | 0.98 | AURKA (0.49) | AURKAPDGFRBCSF1RKITPDGFRA | |
| SCHEMBL4640731 | 0.92 | AURKA (0.49) | AURKAPDGFRBCSF1RKITPDGFRA | |
| SCHEMBL4924647 | 0.92 | AURKA (0.49) | AURKAPDGFRBCSF1RKITPDGFRA | |
| SCHEMBL2798252 | 0.92 | AURKA (0.53) | AURKAPDGFRBCSF1RKITPDGFRA | |
| Hydrochloric Acid SCHEMBL4924377 | 0.92 | AURKA (0.49) | AURKAPDGFRBCSF1RKITPDGFRA | |
| SCHEMBL4925795 | 0.91 | AURKA (0.46) | AURKAPDGFRBCSF1RKITPDGFRA | |
| SCHEMBL2797899 | 0.91 | AURKA (0.47) | AURKAPDGFRBCSF1RKITPDGFRA | |
| Hydrochloric Acid SCHEMBL2800072 | 0.90 | AURKA (0.47) | AURKAPDGFRBCSF1RKITPDGFRA | |
| SCHEMBL4926567 | 0.88 | PDGFRB (0.46) | AURKAPDGFRBCSF1RKITPDGFRA | |
| SCHEMBL4611101 | 0.87 | PDGFRB (0.46) | AURKAPDGFRBCSF1RKITPDGFRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080194556-A1 | Quinazolines and Their Use as Aurora Kinase Inhibitors | ASTRAZENECA AB (SE) | 2008-08-14 | — | — | US | claimed |
| US-20080194556-A1 | Quinazolines and Their Use as Aurora Kinase Inhibitors | ASTRAZENECA AB (SE) | 2008-08-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080194556-A1 | Quinazolines and Their Use as Aurora Kinase Inhibitors | AURKA, AURKC, AURKB | AURKA 1/4885PDGFRB 1853/4885CSF1R 2255/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.